 "Biocon surges 11% ahead of USFDA meet for new drug filing")
Shares of Biocon surged as much as 11% to Rs 360 in intraday ahead of the USFDA meet to discuss its breast cancer drug filing.
The US drug regulator’s Advisory Committee (Adcom) will be meeting on July 13 to discuss trastuzumab filing done by Mylan, Biocon’s partner. Trastuzumab is used to treat metastatic (spread) breast cancer.
The scrip plunged over 9% during Monday’s trade on the BSE as the French inspecting authority (ANSM) found lapses at Biocon's Bengaluru plant.
The stock fell around one third of a percent in the past one month, while its three-day gain
The US drug regulator’s Advisory Committee (Adcom) will be meeting on July 13 to discuss trastuzumab filing done by Mylan, Biocon’s partner. Trastuzumab is used to treat metastatic (spread) breast cancer.
The scrip plunged over 9% during Monday’s trade on the BSE as the French inspecting authority (ANSM) found lapses at Biocon's Bengaluru plant.
The stock fell around one third of a percent in the past one month, while its three-day gain
